CRMI
中國再生醫學

China Regenerative Medicine International Limited
中 國 再 生 醫 學 國 際 有 限 公 司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8158)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

Reference is made to the annual report of China Regenerative Medicine International Limited (the "**Company**") for the year ended 31 December 2025 (the "**2025 Annual Report**") published by the Company on 28 April 2026. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2025 Annual Report.

In addition to the disclosures under the section headed "Share Options" in the Directors' Report as set out in the 2025 Annual Report, the Company would like to supplement the following information:

The New Share Option Scheme was formally adopted by the Company on 27 June 2025, and no new share options had been granted, exercised, cancelled or lapsed under the New Share Option Scheme during the period from the adoption date to 31 December 2025. Accordingly, the number of options available for grant under the New Share Option Scheme as at 1 January 2025 and 31 December 2025 was nil and 30,425,248, respectively.

As set out in the Company's circular dated 4 June 2025 (the "**Circular**"), the aggregate number of shares issuable to all Service Providers (as defined in the Circular) under the New Share Option Scheme shall not exceed 3,042,524 (the "**Service Provider Sublimit**"). As at 1 January 2025 and 31 December 2025, the number of options available for grant under the Service Provider Sublimit was nil and 3,042,524, respectively.

The above additional information does not affect other information contained in the 2025 Annual Report. Save as disclosed above, all other information in the 2025 Annual Report remains unchanged. The Board confirms that all supplementary information disclosed herein is true, accurate and complete and complies with the provisions of the GEM Listing Rules.

By Order of the Board
China Regenerative Medicine International Limited
Wang Chuang
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 12 June 2026

As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Ms. Luo Min; and the independent non-executive Directors are Ms. Huo Chunyu, Mr. Leung Man Fai and Mr. Zhou Xudong.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkexnews.hk for at least seven days from the date of the publication and will be published on the website of the Company at www.crmi.hk.